BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rokkas T, Gisbert JP, Malfertheiner P, Niv Y, Gasbarrini A, Leja M, Megraud F, O'Morain C, Graham DY. Comparative Effectiveness of Multiple Different First-Line Treatment Regimens for Helicobacter pylori Infection: A Network Meta-analysis. Gastroenterology 2021;161:495-507.e4. [PMID: 33839101 DOI: 10.1053/j.gastro.2021.04.012] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
Number Citing Articles
1 Bajwa HUR, Khan MK, Abbas Z, Riaz R, Rehman TU, Abbas RZ, Aleem MT, Abbas A, Almutairi MM, Alshammari FA, Alraey Y, Alouffi A. Nanoparticles: Synthesis and Their Role as Potential Drug Candidates for the Treatment of Parasitic Diseases. Life 2022;12:750. [DOI: 10.3390/life12050750] [Reference Citation Analysis]
2 Mallah N, Zapata-Cachafeiro M, Aguirre C, Ibarra-García E, Palacios-Zabalza I, Macías-García F, Piñeiro-Lamas M, Ibáñez L, Vidal X, Vendrell L, Martin-Arias L, Sáinz-Gil M, Velasco-González V, Bacariza-Cortiñas M, Salgado A, Estany-Gestal A, Figueiras A; EMPHOGEN Group. Synergism interaction between genetic polymorphisms in drug metabolizing enzymes and NSAIDs on upper gastrointestinal haemorrhage: a multicenter case-control study. Ann Med 2022;54:379-92. [PMID: 35114859 DOI: 10.1080/07853890.2021.2016940] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Graham DY, Hernaez R, Rokkas T. Cross-roads for meta-analysis and network meta-analysis of H. pylori therapy. Gut 2022;71:643-50. [PMID: 34750206 DOI: 10.1136/gutjnl-2021-326170] [Reference Citation Analysis]
4 Ouyang Y, Wang M, Xu YL, Zhu Y, Lu NH, Hu Y. Amoxicillin-vonoprazan dual therapy for Helicobacter pylori eradication: A systematic review and meta-analysis. J Gastroenterol Hepatol 2022. [PMID: 35716370 DOI: 10.1111/jgh.15917] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Yang C, Li S, Huang T, Lin H, Jiang Z, He Y, Yuan J, An H. Effectiveness and safety of vonoprazan-based regimen for Helicobacter pylori eradication: A meta-analysis of randomized clinical trials. J Clin Pharm Ther 2022. [PMID: 35247003 DOI: 10.1111/jcpt.13637] [Reference Citation Analysis]
6 Dharan M, Wozny D. Helicobacter pylori infection and small intestinal bacterial overgrowth–more than what meets the eye. World J Clin Cases 2022; 10(21): 7209-7214 [DOI: 10.12998/wjcc.v10.i21.7209] [Reference Citation Analysis]
7 Ang D, Koo SH, Chan YH, Tan TY, Soon GH, Tan CK, Lin KW, Krishnasamy-Balasubramanian JK, Wong YJ, Kumar R, R R, Tan Y, Ong PJ, Tan YJ, Li JW, Kwek AB, Ang TL. Clinical trial: seven-day vonoprazan- versus 14-day proton pump inhibitor-based triple therapy for first-line Helicobacter pylori eradication. Aliment Pharmacol Ther 2022. [PMID: 35665947 DOI: 10.1111/apt.17070] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Fernández-Salazar L, Campillo A, Rodrigo L, Pérez-Aisa Á, González-Santiago JM, Segarra Ortega X, Denkovski M, Brglez Jurecic N, Bujanda L, Gómez Rodríguez BJ, Ortuño J, Georgopoulos S, Jonaitis L, Puig I, P Nyssen O, Megraud F, O'Morain C, P Gisbert J. Effectiveness and Safety of High-Dose Dual Therapy: Results of the European Registry on the Management of Helicobacterpylori Infection (Hp-EuReg). J Clin Med 2022;11:3544. [PMID: 35743627 DOI: 10.3390/jcm11123544] [Reference Citation Analysis]
9 Shiotani A, Roy P, Lu H, Graham DY. Helicobacter pylori diagnosis and therapy in the era of antimicrobial stewardship. Therap Adv Gastroenterol 2021;14:17562848211064080. [PMID: 34987609 DOI: 10.1177/17562848211064080] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
10 Xirouchakis E, Georgopoulos SD. Evaluating treatments with rifabutin and amoxicillin for eradication of Helicobacter pylori infection in adults: a systematic review. Expert Opin Pharmacother 2021;:1-10. [PMID: 34595999 DOI: 10.1080/14656566.2021.1982894] [Reference Citation Analysis]
11 Gisbert JP, Alcedo J, Amador J, Bujanda L, Calvet X, Castro-Fernández M, Fernández-Salazar L, Gené E, Lanas Á, Lucendo AJ, Molina-Infante J, Nyssen OP, Pérez-Aisa A, Puig I. V Spanish Consensus Conference on Helicobacter pylori infection treatment. Gastroenterol Hepatol 2021:S0210-5705(21)00229-6. [PMID: 34629204 DOI: 10.1016/j.gastrohep.2021.07.011] [Reference Citation Analysis]
12 Wasielica-berger J, Gugnacki P, Mlynarczyk M, Rogalski P, Swidnicka-siergiejko A, Antonowicz S, Krzyzak M, Maslach D, Dabrowski A, Daniluk J. Comparative Effectiveness of Various Eradication Regimens for Helicobacter Pylori Infection in the Northeastern Region of Poland. IJERPH 2022;19:6921. [DOI: 10.3390/ijerph19116921] [Reference Citation Analysis]
13 Wang K, Lou D, Dai W, Fu R, Ma Z. Comparison of sequential therapy with concomitant therapy in first-line treatment of Helicobacter pylori: an updated meta-analysis. J Med Microbiol 2022;71. [PMID: 35041577 DOI: 10.1099/jmm.0.001490] [Reference Citation Analysis]
14 Rokkas T, Georgopoulos S, Michopoulos S, Ntouli V, Liatsos C, Puig I, Nyssen OP, Mégraud F, O'Morain C, Gisbert JP; Hp-EuReg Investigators. Assessment of first-line eradication treatment in Greece: data from the European Registry on Helicobacter pylori management (Hp-EuReg). Ann Gastroenterol 2022;35:42-7. [PMID: 34987287 DOI: 10.20524/aog.2021.0670] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Chen B, Li X, Cai T, Wang F. Short-term and long-term alterations of gastrointestinal microbiota with different H. pylori eradication regimens: A meta-analysis. Front Cell Infect Microbiol 2022;12:913384. [DOI: 10.3389/fcimb.2022.913384] [Reference Citation Analysis]
16 Shah S, Hubscher E, Pelletier C, Jacob R, Vinals L, Yadlapati R. Helicobacter pylori infection treatment in the United States: clinical consequences and costs of eradication treatment failure. Expert Rev Gastroenterol Hepatol 2022;16:341-57. [PMID: 35315732 DOI: 10.1080/17474124.2022.2056015] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]